Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

130.81 -0.83 (-0.63%)
Streaming Delayed Price Updated: 3:04 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
50 51 Next >
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst
Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks. 
Via Benzinga
Topics World Trade
3 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year
FDA grants accelerated approval to Novartis' Vanrafia for IgA nephropathy, with Phase 3 data in 2026 expected to support traditional approval. 
Via Benzinga
Is the Market Bullish or Bearish on Novartis?
 
Via Benzinga
Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval
The companies are going head to head in kidney disease. Here's why Novartis could have a slight advantage. 
Via Investor's Business Daily
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction. 
Via Benzinga
The Top 3 Vanguard ETFs of 2025 (so Far) Share This 1 Striking Common Denominator
Via The Motley Fool
Topics Bonds ETFs
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) Technical Analysis observations.
Exploring NOVARTIS AG-SPONSORED ADR's Technical Signals and Breakout Potential: Promising Signs: NOVARTIS AG-SPONSORED ADR Setting the Stage for a Breakout. 
Via Chartmill
No Fear And No Panic After A 10% Correction = No Bottom
In this video lesson, I discuss the overall market, my books, and my game plan moving forward after Friday's ugly sell-off. 
Via Talk Markets
Topics Stocks / Equities
FDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool
FDA approves Novartis' Pluvicto for advanced prostate cancer patients who have received ARPI therapy. 
Via Benzinga
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is an undervalued gem with solid fundamentals.
NOVARTIS AG-SPONSORED ADR has caught the attention as a great value stock. NYSE:NVS excels in profitability, solvency, and liquidity, all while being very reasonably priced. 
Via Chartmill
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements
EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory reviews continue. 
Via Benzinga
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders
Monte Rosa's MRT-6160 shows promising Phase 1 results, with Novartis backing its development in a deal that could reach $2.1B in milestone payments. 
Via Benzinga
Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy
Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a treatment option. 
Via Benzinga
The Best Vanguard ETF to Invest $1,000 in Right Now
Via The Motley Fool
Topics ETFs
These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy?
Via The Motley Fool
Topics ETFs Stocks
Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss
Teladoc Health teams up with Eli Lilly's LillyDirect to improve Zepbound access, offering direct home delivery and comprehensive obesity care support. 
Via Benzinga
Novartis Earns Near-Best Overall Rating As Profit Growth Climbs
Novartis ranks No. 1 among in the 33-stock Medical-Ethical Drugs industry group. Novartis got a Composite Rating upgrade to 96 on Wednesday. 
Via Investor's Business Daily
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) stands out as a stock that provides good value for the fundamentals it showcases.
Uncover the potential of NOVARTIS AG-SPONSORED ADR, an undervalued stock. NYSE:NVS maintains a strong financial position and offers an appealing valuation. 
Via Chartmill
Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction
Highly ranked Novartis is forming the right side of a long cup base with a buy point of 120.92. And it's literally running higher. 
Via Investor's Business Daily
Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy
Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer adverse events. 
Via Benzinga
3 Dividend Stocks That Are No-Brainer Buys Right Now
Via The Motley Fool
Court Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program
A federal court rejected Novartis' legal challenge to the Medicare Drug Price Negotiation Program, ruling that it does not impose unconstitutional fines, takings, or compelled speech. 
Via Benzinga
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing... 
Via Benzinga
This Kraft Heinz Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
 
Via Benzinga
Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal
Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its cardiovascular portfolio. 
Via Benzinga
Super Bowl Commercials 2025: Complete List of Super Bowl LIX Ads And Companies Behind Them
The list of Super Bowl LIX commercials and the companies behind the Super Bowl ads. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
50 51 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.